LIVIVO - Search results -

Search results

Result 1 - 10 of total 487

Search options

Article: [Current status of diagnosis and treatment in diffuse large B-cell lymphoma].

Shimada, Kazuyuki

Rinsho ketsueki] The Japanese journal of clinical hematology

2021 Volume 62, Issue 8, Page(s) 1077–1084

Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma affecting about 14,000 patients per year in Japan. Recent progress in molecular genetic investigation has clarified the underlying mechanism of this heterogeneous disease ...

Abstract	Diffuse large B-cell lymphoma (DLBCL) is the most common type of malignant lymphoma affecting about 14,000 patients per year in Japan. Recent progress in molecular genetic investigation has clarified the underlying mechanism of this heterogeneous disease applied to therapeutic developments. R-CHOP therapy was established as a standard regimen for DLBCL and provides a cure in many patients. However, about 30-40% of patients still develop relapsed/refractory (R/R) disease. The development of effective treatments for R/R DLBCL patients is thus an urgent issue. The development of immunotherapy for intractable DLBCL patients such as anti-CD19 chimeric antigen receptor (CAR)-T therapy and bispecific T-cell engager (BiTE) has recently progressed. This new modality demonstrates efficacy in patients with resistance to conventional anticancer drugs. The advent of emerging immunotherapy is a paradigm shift in lymphoma treatment and is important for clinicians to catch up with these changes.
MeSH term(s)	Antigens, CD19 ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Immunotherapy, Adoptive ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/therapy ; Receptors, Chimeric Antigen/therapeutic use ; Rituximab/therapeutic use
Chemical Substances	Antigens, CD19 ; Receptors, Chimeric Antigen ; Rituximab (4F4X42SYQ6)
Language	Japanese
Publishing date	2021-09-08
Publishing country	Japan
Document type	Journal Article
ZDB-ID	390900-1
ISSN	0485-1439
ISSN	0485-1439
DOI	10.11406/rinketsu.62.1077
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1175: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 535: Show issues

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Current achievements and future perspectives in the research on intravascular large B-cell lymphoma].

Shimada, Kazuyuki

Rinsho ketsueki] The Japanese journal of clinical hematology

2020 Volume 62, Issue 6, Page(s) 631–640

Abstract: Intravascular large B-cell lymphoma is a rare disease entity of extranodal large B-cell lymphoma and is characterized by selective growth of tumor cells in the lumina of small vessels in systemic organs. The challenge in obtaining sufficient tumor cells ... ...

Abstract	Intravascular large B-cell lymphoma is a rare disease entity of extranodal large B-cell lymphoma and is characterized by selective growth of tumor cells in the lumina of small vessels in systemic organs. The challenge in obtaining sufficient tumor cells from biopsy specimens has hampered the elucidation of underlying biology. Recent advances in xenograft models and plasma cell-free DNA have revealed that the intravascular large B-cell lymphoma has genetic features similar to those of activated B-cell-like diffuse large B-cell lymphoma and frequent genetic alterations in immune-check point related genes. In terms of clinical aspects, considering the improvement in the clinical outcomes and higher risk of secondary central nervous system (CNS) involvement in the rituximab era, phase 2 trial of R-CHOP therapy combined with high-dose methotrexate and intrathecal chemotherapy as CNS-oriented therapy was conducted. The trial, named the PRIMEUR-IVL study, displayed good progression-free survival and low cumulative incidence of secondary CNS involvement. Further research is necessary to enable a deeper understanding of the pathophysiology of the disease and further improve the clinical outcomes.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols ; Central Nervous System Neoplasms/drug therapy ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Prednisone/therapeutic use ; Rituximab/therapeutic use ; Vincristine/therapeutic use
Chemical Substances	Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT)
Language	Japanese
Publishing date	2020-12-04
Publishing country	Japan
Document type	Journal Article
ZDB-ID	390900-1
ISSN	0485-1439
ISSN	0485-1439
DOI	10.11406/rinketsu.62.631
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1175: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 535: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Molecular pathogenesis and treatment strategy in diffuse large B-cell lymphoma.

Shimada, Kazuyuki

Rinsho ketsueki] The Japanese journal of clinical hematology

2017 Volume 58, Issue 10, Page(s) 2033–2042

Abstract: Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, accounting for 30%-40% of all types of malignant lymphoma. Importantly, two distinct molecular subtypes, germinal center B-cell (GCB) type and activated B- ... ...

Abstract	Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma, accounting for 30%-40% of all types of malignant lymphoma. Importantly, two distinct molecular subtypes, germinal center B-cell (GCB) type and activated B-cell (ABC) type, arising from B lymphocyte differentiation based on the gene expression profiling opened doors to uncover molecular pathogenesis in DLBCL. Since 2010, next-generation sequencing analyses have been revealing the landscape of genetic mutations in DLBCL. Reportedly, GCB DLBCL is characterized by the accumulation of genetic abnormalities of epigenetic modifiers. Conversely, the hallmark of ABC DLBCL is the constitutive activation of the NKκB signaling pathway due to mutations in related genes. From recent prospective trials, conventional R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen, which is the current standard regimen for DLBCL, has been acknowledged as a well-established regimen for DLBCL. Currently, the development of a plethora of drugs targeting the activated signaling pathway and immune microenvironments is ongoing. To overcome this intractable disease with the present treatment, the breakthroughs based on molecular pathogenesis are required.
Language	Japanese
Publishing date	2017
Publishing country	Japan
Document type	Journal Article
ZDB-ID	390900-1
ISSN	0485-1439
ISSN	0485-1439
DOI	10.11406/rinketsu.58.2033
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1175: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 535: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Current progress and future perspectives of research on intravascular large B-cell lymphoma.

Shimada, Kazuyuki / Kiyoi, Hitoshi

Cancer science

2021 Volume 112, Issue 10, Page(s) 3953–3961

Abstract: Intravascular large B-cell lymphoma is a rare disease of the large B cells characterized by selective growth in the lumina of small vessels in systemic organs. Since first reported in 1959, the difficulty of obtaining sufficient tumor cells from biopsy ... ...

Abstract	Intravascular large B-cell lymphoma is a rare disease of the large B cells characterized by selective growth in the lumina of small vessels in systemic organs. Since first reported in 1959, the difficulty of obtaining sufficient tumor cells from biopsy specimens has hampered the elucidation of its underlying biology. Recent progress using xenograft models and plasma cell-free DNA has uncovered genetic features that are similar to those of activated B-cell type diffuse large B-cell lymphoma, including MYD88 and CD79B mutations and frequent alterations in immune check point-related genes such as PD-L1 and PD-L2. Given the improvement in clinical outcomes and a higher risk of secondary central nervous system (CNS) involvement in the rituximab era, a phase 2 trial of R-CHOP combined with high-dose methotrexate and intrathecal chemotherapy as a CNS-oriented therapy has been conducted. This trial, the PRIMEUR-IVL study, has displayed good progression-free survival and a low cumulative incidence of secondary CNS involvement. Long-term follow-up within this trial is still ongoing. Further understanding of the pathophysiology of the disease and improvements in clinical outcomes are still needed.
MeSH term(s)	Antimetabolites, Antineoplastic/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; B7-H1 Antigen/genetics ; Cell Cycle Checkpoints/genetics ; Central Nervous System Neoplasms/prevention & control ; Clinical Trials, Phase II as Topic ; Cyclophosphamide/therapeutic use ; Doxorubicin/therapeutic use ; Female ; Forecasting ; Heterografts ; Humans ; Injections, Spinal ; Lymphoma, Large B-Cell, Diffuse/diagnostic imaging ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Lymphoma, Large B-Cell, Diffuse/genetics ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Methotrexate/therapeutic use ; Middle Aged ; Neoplasm Transplantation ; Prednisone/therapeutic use ; Programmed Cell Death 1 Ligand 2 Protein/genetics ; Progression-Free Survival ; Rituximab/therapeutic use ; Vascular Neoplasms/diagnostic imaging ; Vascular Neoplasms/drug therapy ; Vascular Neoplasms/genetics ; Vascular Neoplasms/pathology ; Vincristine/therapeutic use
Chemical Substances	Antimetabolites, Antineoplastic ; B7-H1 Antigen ; CD274 protein, human ; PDCD1LG2 protein, human ; Programmed Cell Death 1 Ligand 2 Protein ; R-CHOP protocol ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisone (VB0R961HZT) ; Methotrexate (YL5FZ2Y5U1)
Language	English
Publishing date	2021-08-09
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2115647-5
ISSN	1349-7006 ; 1347-9032
ISSN (online)	1349-7006
ISSN	1347-9032
DOI	10.1111/cas.15091
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: [The criteria for the selection of antihypertensive drugs by JSH2014 guidelines].

Shimada, Kazuyuki

Nihon rinsho. Japanese journal of clinical medicine

2015 Volume 73, Issue 11, Page(s) 1841–1845

Abstract: The preventive effects of antihypertensive drugs on cardiovascular disease are determined by the degree to which blood pressure decreases rather than its class. Appropriate antihypertensive drugs should be selected considering compelling indications, ... ...

Abstract	The preventive effects of antihypertensive drugs on cardiovascular disease are determined by the degree to which blood pressure decreases rather than its class. Appropriate antihypertensive drugs should be selected considering compelling indications, contraindications and conditions that require the careful use of drugs and the presence or absence of complications. In hypertensive patients without compelling indications, the antihypertensive drug to be first administered should be selected from Ca channel blockers, angiotensin-receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors and diuretics. The use of two or three drugs in combination is often necessary to achieve the target of blood pressure control. Combination therapy with different classes of antihypertensive drugs exhibits potent hypotensive effects, and is useful for achieving the target of blood pressure control.
MeSH term(s)	Angiotensin Receptor Antagonists/therapeutic use ; Antihypertensive Agents/therapeutic use ; Clinical Trials as Topic ; Contraindications ; Drug Combinations ; Humans ; Hypertension/drug therapy ; Practice Guidelines as Topic
Chemical Substances	Angiotensin Receptor Antagonists ; Antihypertensive Agents ; Drug Combinations
Language	Japanese
Publishing date	2015-11
Publishing country	Japan
Document type	Journal Article
ZDB-ID	390903-7
ISSN	0047-1852
ISSN	0047-1852
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 429: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Current understanding and future prospects for intravascular large B-cell lymphoma].

Shimada, Kazuyuki

Rinsho ketsueki] The Japanese journal of clinical hematology

2015 Volume 56, Issue 8, Page(s) 1032–1037

Abstract: Intravascular large B-cell lymphoma (IVLBCL) is a rare distinct disease entity of the extranodal large B-cell lymphoma type, characterized by the selective growth of tumor cells in the lumina of small vessels of various organs. Lack of remarkable ... ...

Abstract	Intravascular large B-cell lymphoma (IVLBCL) is a rare distinct disease entity of the extranodal large B-cell lymphoma type, characterized by the selective growth of tumor cells in the lumina of small vessels of various organs. Lack of remarkable lymphadenopathy and non-specific clinical abnormalities including fever of unknown origin and lactate dehydrogenase elevation generally make timely and accurate diagnosis difficult. Recent diagnostic advances in the detection of this disease using FDG-PET/CT and random skin biopsies are expected to increase the diagnostic yield. Regarding the therapeutic aspects of this disease, improvement of clinical outcomes by the application of anti-CD20 monoclonal antibody, rituximab, and a high risk of CNS recurrence have been indicated. Thus, a prospective phase II trial of immunochemotherapy combined with CNS prophylaxis is now ongoing. Previously, the difficulty of obtaining sufficient tumor samples hampered biological investigations but the novel technique developing xenograft models is opening the door to uncovering the underlying mechanisms by focusing on the fundamental biological question: "Why do tumor cells become lodged in the lumina of vessels?" This review describes the current understanding of research on IVLBCL and discusses the future prospects for this disease entity.
MeSH term(s)	Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Clinical Trials, Phase II as Topic ; Hematopoietic Stem Cell Transplantation ; Humans ; Lymphoma, B-Cell/therapy ; Positron-Emission Tomography ; Transplantation, Autologous ; Vascular Neoplasms/pathology ; Vascular Neoplasms/therapy
Language	Japanese
Publishing date	2015-08
Publishing country	Japan
Document type	English Abstract ; Journal Article
ZDB-ID	390900-1
ISSN	0485-1439
ISSN	0485-1439
DOI	10.11406/rinketsu.56.1032
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1175: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 535: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Brief overview of the guidelines for the use of 24 hour ambulatory blood pressure monitoring (ABPM)].

Shimada, Kazuyuki

Nihon rinsho. Japanese journal of clinical medicine

2014 Volume 72, Issue 8, Page(s) 1363–1367

Abstract: The guidelines for the use of ambulatory blood pressure monitoring published from Japanese Circulation Society in 2010 was briefly overviewed. The accuracy of devices now used in clinical practice in Japan is of sufficient grade. The thresholds for ... ...

Abstract	The guidelines for the use of ambulatory blood pressure monitoring published from Japanese Circulation Society in 2010 was briefly overviewed. The accuracy of devices now used in clinical practice in Japan is of sufficient grade. The thresholds for hypertension diagnosis based on ABPM have been determined with international concensus. The evaluation of ABPM data and the clinical indications for ABPM are suggested. Particularly, white-coat hypertension, masked hypertension, nocturnal hypertension, morning hypertension and diurnal blood pressure variation are conditions for which ABPM is very useful for the detection, treatment decision and follow-up. Hypertension treatment would be very much improved by the introduction of ABPM into clinical practice.
MeSH term(s)	Blood Pressure/physiology ; Blood Pressure Monitoring, Ambulatory ; Circadian Rhythm/physiology ; Humans ; Hypertension/diagnosis ; Hypertension/therapy ; Japan ; Practice Guidelines as Topic ; Time Factors
Language	Japanese
Publishing date	2014-08
Publishing country	Japan
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	390903-7
ISSN	0047-1852
ISSN	0047-1852
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 429: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma in the Gastrointestinal Tract in the Modern Era.

Ishikawa, Eri / Nakamura, Masanao / Satou, Akira / Shimada, Kazuyuki / Nakamura, Shotaro

Cancers

2022 Volume 14, Issue 2

Abstract: Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) typically arises from sites such as the stomach, where there is no organized lymphoid tissue. Close associations ... ...

Abstract	Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma) typically arises from sites such as the stomach, where there is no organized lymphoid tissue. Close associations between
Language	English
Publishing date	2022-01-17
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2527080-1
ISSN	2072-6694
ISSN	2072-6694
DOI	10.3390/cancers14020446
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article: [Treatment strategy for intravascular large B-cell lymphoma].

Shimada, Kazuyuki

Nihon rinsho. Japanese journal of clinical medicine

2012 Volume 70 Suppl 2, Page(s) 704–708

MeSH term(s)	Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Antineoplastic Agents/therapeutic use ; Humans ; Lymphoma, Large B-Cell, Diffuse/diagnosis ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Rituximab ; Vascular Neoplasms/diagnosis ; Vascular Neoplasms/drug therapy
Chemical Substances	Antibodies, Monoclonal, Murine-Derived ; Antineoplastic Agents ; Rituximab (4F4X42SYQ6)
Language	Japanese
Publishing date	2012-04
Publishing country	Japan
Document type	Journal Article
ZDB-ID	390903-7
ISSN	0047-1852
ISSN	0047-1852
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 429: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Treatment strategy for central nervous system involvement in intravascular large B-cell lymphoma].

Shimada, Kazuyuki

Brain and nerve = Shinkei kenkyu no shinpo

2011 Volume 63, Issue 5, Page(s) 467–472

Abstract: Intravascular large B-cell lymphoma (IVLBCL) is a distinct disease entity of non-Hodgkin lymphoma which is characterized in the current WHO classification by the selective growth of tumour cells in the lumina of small vessels of various organs. This rare ...

Abstract	Intravascular large B-cell lymphoma (IVLBCL) is a distinct disease entity of non-Hodgkin lymphoma which is characterized in the current WHO classification by the selective growth of tumour cells in the lumina of small vessels of various organs. This rare disease entity has a high incidence of central nervous system (CNS) involvement at diagnosis. Although several retrospective analyses indicate that the treatment of this lymphoma has improved in the post-rituximab era, risk of CNS recurrence at 3 years still reaches ~25%. Considering the poor prognosis of IVLBCL patients with CNS recurrence, elucidating the optimal treatment strategies for this serious complication is vital in order to further improve its clinical management. Meanwhile, the efficacy of CNS prophylaxis for specific subtypes of lymphoma, for example Burkitt lymphoma and acute lymphocytic leukemia/lymphoblastic lymphoma, has been established, and several risk factors of CNS relapse for diffuse large B-cell lymphoma (DLBCL) were indicated by previous analyses. Considering that almost all IVLBCL patients have similar risk factors, CNS prophylaxis could also be effective, and thereby give rise to better clinical outcomes, in the treatment of IVLBCL, especially for patients without CNS involvement at initial diagnosis. Intensity regimens for CNS and systemic chemotherapy could be useful for patients with CNS involvement at initial diagnosis. This review describes the current understanding of clinical outcome and CNS involvement in IVLBCL, and discusses the optimal treatment strategy and future perspectives for CNS involvement of this rare lymphoma.
MeSH term(s)	Antibodies, Monoclonal, Murine-Derived/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bleomycin/administration & dosage ; Central Nervous System Neoplasms/drug therapy ; Central Nervous System Neoplasms/pathology ; Central Nervous System Neoplasms/prevention & control ; Cyclophosphamide/administration & dosage ; Doxorubicin/administration & dosage ; Humans ; Lymphoma, Large B-Cell, Diffuse/drug therapy ; Methotrexate/administration & dosage ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local/prevention & control ; Prednisolone/administration & dosage ; Rituximab ; Vascular Neoplasms/drug therapy ; Vincristine/administration & dosage
Chemical Substances	Antibodies, Monoclonal, Murine-Derived ; Bleomycin (11056-06-7) ; Rituximab (4F4X42SYQ6) ; Vincristine (5J49Q6B70F) ; Doxorubicin (80168379AG) ; Cyclophosphamide (8N3DW7272P) ; Prednisolone (9PHQ9Y1OLM) ; Methotrexate (YL5FZ2Y5U1)
Language	Japanese
Publishing date	2011-05
Publishing country	Japan
Document type	English Abstract ; Journal Article ; Review
ZDB-ID	390389-8
ISSN	1344-8129 ; 1881-6096 ; 0006-8969
ISSN (online)	1344-8129
ISSN	1881-6096 ; 0006-8969
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 398: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito